Grafix® Manuscript From Osiris Therapeutics, Inc.’ Multi-center, Randomized, Controlled Clinical Trial Available Electronically In Peer-Reviewed Journal

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix® to control in patients with chronic diabetic foot ulcers (DFUs), which was accepted for publication in the International Wound Journal, is now available online and will also be in an upcoming issue.

Help employers find you! Check out all the jobs and post your resume.